CLINICAL TRIALS FOR SEVERE SEPSIS: Past Failures, and Future Hopes

This publication has 49 references indexed in Scilit:

• Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock
  The Lancet, 1998
• p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group
  Published by American Medical Association (AMA) ,1997
• The Effects of Ibuprofen on the Physiology and Survival of Patients with Sepsis
  New England Journal of Medicine, 1997
• Sir Isaac Newton, sepsis, SIRS, and CARS
  Critical Care Medicine, 1996
• Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis
  JAMA, 1995
• A second large controlled clinical study of E5, a monoclonal antibody to endotoxin
  Critical Care Medicine, 1995
• Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group
  Published by American Medical Association (AMA) ,1995
• Gram-positive organisms and sepsis
  Archives of internal medicine (1960), 1994
• Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis
  Chest, 1992
• The Pathogenesis of Sepsis
  Annals of Internal Medicine, 1991